BMY - שולי רווח נקי ממכירות BMS

לוגו של חברה ציבורית Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (BMY) is updating its portfolio through the acquisition of biotech startups in an effort to overcome declining revenues. Adjusted net sales margins reflect this search for a market bottom, with this metric settling at 18.50. However, Medicare pressure and patent losses for Revlimid create risks. Stability is supported by automated reactors and machine learning, which accelerate the synthesis of new molecules.

שולי מכירות של החברה bms.com (BMY): לתקופה 04.07.2022 - 20.11.2026

פילוחים אנליטיים של חברת Bristol-Myers Squibb

- שווי שוק ותחזית יעד של אנליסטים:
הערכת שווי פונדמנטלית:bms.com, BMY
מוצר המיוצר על ידי BMS

For investors, assessing the efficiency of Bristol-Myers Squibb (BMY) is currently critical due to the loss of patent protection for key drugs and the necessity of refreshing the portfolio through acquisitions. By analyzing the net profit margin, we determine the share of profit remaining after all expenses, which allows us to distinguish a temporary dip in profitability from a systemic crisis, thereby preventing the risk of freezing capital in a degrading business.